公司概覽
業務類別 Biotechnology
業務概覽 BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
公司地址 770 Lindaro Street, San Rafael, CA, USA, 94901
電話號碼 +1 415 506-6700
傳真號碼 +1 415 382-7889
公司網頁 https://www.biomarin.com
員工數量 3221
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Cristin Hubbard Executive Vice President and Chief Commercial Officer 美元 662.31K 21/04/2026
Ms. Rashmi Virendra Ramchandani Vice President and Chief Accounting Officer -- 21/04/2026
Mr. Alexander Hardy Director, President and Chief Executive Officer 美元 1.13M 21/04/2026
Mr. G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary -- 21/04/2026
Mr. Brian R. Mueller Executive Vice President and Chief Financial Officer 美元 721.15K 21/04/2026
Dr. Charles Greg Guyer, PhD Chief Technical Officer and Executive Vice President 美元 697.12K 21/04/2026
Dr. Gregory R. Friberg, M.D. Executive Vice President and Chief Research and Development Officer 美元 705.65K 21/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Richard A. Meier Chairman of the Board 21/04/2026
Dr. Willard H. Dere, M.D. Independent Director 21/04/2026
Mr. Alexander Hardy Director, President and Chief Executive Officer 21/04/2026
Mr. Robert J. Hombach Independent Director 21/04/2026
Dr. Maykin Ho, PhD Independent Director 21/04/2026
Mr. Ian T. Clark Independent Director 21/04/2026
Ms. Elizabeth McKee Anderson, M.B.A. Independent Director 21/04/2026
Mr. Timothy P. Walbert Independent Director 21/04/2026
Ms. Barbara W. Bodem Independent Director 21/04/2026
Mr. Mark Joseph Enyedy Independent Director 21/04/2026
Dr. Athena Countouriotis, M.D. Independent Director 21/04/2026
 
所屬ETF (更新日期: 02/05/2026 04:43)
代號 名稱 佔比% 持有日期
BIBProShares Ultra Nasdaq Biotechnology0.004%29/04/2026
AVMCAvantis U.S. Mid Cap Equity ETF0.004%29/04/2026
MSLCMorgan Stanley Pathway Large Cap Eq ETF0.004%29/04/2026
FTXHFirst Trust Nasdaq Pharmaceuticals ETF0.004%29/04/2026
JIIIJanus Henderson Income ETF0.004%29/04/2026
FADFirst Trust Multi Cap Gr AlphaDEX® ETF0.003%29/04/2026
MVVProShares Ultra MidCap4000.003%29/04/2026
GUSAGoldman Sachs MarketBeta US 1000 Eq ETF0.003%29/04/2026
TILTFlexShares Mstar US Mkt Factors Tilt ETF0.003%29/04/2026
MKTNFederated Hermes MDT Market Neutral ETF0.003%29/04/2026
SYZLazard US Systematic Small Cap Eq ETF0.003%29/04/2026
LCFTouchstone US Large Cap Focused ETF0.003%29/04/2026
JHMLJHancock Multifactor Large Cap ETF0.003%29/04/2026
SMOXHorizon Small/Mid Cap Core Equity ETF0.003%28/04/2026
AVLCAvantis U.S. Large Cap Equity ETF0.002%29/04/2026
DXUVDimensional US Vector Equity ETF0.002%29/04/2026
LRNDNYLI U.S. Large Cap R&D Leaders ETF0.002%29/04/2026
NBCRNeuberger Core Equity ETF0.002%29/04/2026
INVNAlger Russell Innovation ETF0.002%29/04/2026
IALTiShares Systematic Alternatives Actv ETF0.002%24/04/2026
  1    2    3    4    5   6    7    8    9    10    11    12    13  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.